SRF’s Q4FY23 print for chemical business (EBIT up 47% YoY) benefited from strong ref gas and fluorospecialty business. Despite the risk of pricing in ref-gas and down- cycle in agro-chemicals, company has guided for chemical segment revenue growth of 20%+, and EBIT margin improvement in FY24 (vs FY23).